Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

Line Jee Hartmann Rasmussen; Martin Schultz; Anne Gaardsting; Steen Ladelund; Peter Garred; Kasper Iversen; Jesper Eugen-Olsen; Morten Helms; Kim Peter David; Andreas Kjaer; Anne-Mette Lebech; Gitte Kronborg

doi:10.1002/ijc.30732

Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

Line Jee Hartmann Rasmussen, Martin Schultz, Anne Gaardsting, Steen Ladelund, Peter Garred, Kasper Iversen, Jesper Eugen-Olsen, Morten Helms, Kim Peter David, Andreas Kjaer, Anne-Mette Lebech, Gitte Kronborg

17 Citations (Scopus)

39 Downloads (Pure)

Abstract

In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.

Original language	English
Journal	International Journal of Cancer
Volume	141
Pages (from-to)	191-199
ISSN	0020-7136
DOIs	https://doi.org/10.1002/ijc.30732
Publication status	Published - 1 Jul 2017

Keywords

Age Factors
Aged
Biomarkers, Tumor
C-Reactive Protein
Denmark
Female
Humans
Inflammation
Lectins
Male
Mannose-Binding Lectins
Middle Aged
Neoplasms
Receptors, Urokinase Plasminogen Activator
Serum Amyloid P-Component
Sex Characteristics
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ijc.30732Licence: CC BY-NC

Rasmussen_et_al-2017-International_Journal_of_CancerFinal published version, 406 KBLicence: CC BY-NC

Cite this

Rasmussen, L. J. H., Schultz, M., Gaardsting, A., Ladelund, S., Garred, P., Iversen, K., Eugen-Olsen, J., Helms, M., David, K. P., Kjaer, A., Lebech, A-M., & Kronborg, G. (2017). Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. International Journal of Cancer, 141, 191-199. https://doi.org/10.1002/ijc.30732

Inflammatory biomarkers and cancer : CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. / Rasmussen, Line Jee Hartmann; Schultz, Martin; Gaardsting, Anne et al.

In: International Journal of Cancer, Vol. 141, 01.07.2017, p. 191-199.

Research output: Contribution to journal › Journal article › Research › peer-review

Rasmussen, LJH, Schultz, M, Gaardsting, A, Ladelund, S, Garred, P, Iversen, K, Eugen-Olsen, J, Helms, M, David, KP, Kjaer, A , Lebech, A-M & Kronborg, G 2017, 'Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer', International Journal of Cancer, vol. 141, pp. 191-199. https://doi.org/10.1002/ijc.30732

@article{3e3bbecc18844133b6194c2d574af7e4,

title = "Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer",

abstract = "In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.",

keywords = "Age Factors, Aged, Biomarkers, Tumor, C-Reactive Protein, Denmark, Female, Humans, Inflammation, Lectins, Male, Mannose-Binding Lectins, Middle Aged, Neoplasms, Receptors, Urokinase Plasminogen Activator, Serum Amyloid P-Component, Sex Characteristics, Journal Article, Research Support, Non-U.S. Gov't",

author = "Rasmussen, {Line Jee Hartmann} and Martin Schultz and Anne Gaardsting and Steen Ladelund and Peter Garred and Kasper Iversen and Jesper Eugen-Olsen and Morten Helms and David, {Kim Peter} and Andreas Kjaer and Anne-Mette Lebech and Gitte Kronborg",

note = "{\textcopyright} 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/ijc.30732",

language = "English",

volume = "141",

pages = "191--199",

journal = "Radiation Oncology Investigations",

issn = "0020-7136",

publisher = "JohnWiley & Sons, Inc.",

}

TY - JOUR

T1 - Inflammatory biomarkers and cancer

T2 - CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

AU - Rasmussen, Line Jee Hartmann

AU - Schultz, Martin

AU - Gaardsting, Anne

AU - Ladelund, Steen

AU - Garred, Peter

AU - Iversen, Kasper

AU - Eugen-Olsen, Jesper

AU - Helms, Morten

AU - David, Kim Peter

AU - Kjaer, Andreas

AU - Lebech, Anne-Mette

AU - Kronborg, Gitte

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.

AB - In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.

KW - Age Factors

KW - Aged

KW - Biomarkers, Tumor

KW - C-Reactive Protein

KW - Denmark

KW - Female

KW - Humans

KW - Inflammation

KW - Lectins

KW - Male

KW - Mannose-Binding Lectins

KW - Middle Aged

KW - Neoplasms

KW - Receptors, Urokinase Plasminogen Activator

KW - Serum Amyloid P-Component

KW - Sex Characteristics

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1002/ijc.30732

DO - 10.1002/ijc.30732

M3 - Journal article

C2 - 28393357

SN - 0020-7136

VL - 141

SP - 191

EP - 199

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

ER -

Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this